:

ANDROID 17 BRINGS AI WIDGETS AND SCREEN TIME CONTROLS

INDUSTRY DESK1 MIN READ
TUE, MAY 12, 2026

■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE

Google has unveiled Android 17's major features, headlined by AI-generated widgets and improved dictation tools. The update also includes non-AI improvements like an emoji redesign and new app distraction controls.

Android 17 leans heavily into artificial intelligence, with AI-enabled widgets and enhanced voice dictation among the centerpieces. The system will generate customizable widgets based on user preferences and behavior. Beyond AI, Android 17 addresses user control and customization. A new screentime management tool helps users identify and avoid distracting applications, while a comprehensive emoji overhaul modernizes the platform's visual language. Google revealed the updates during its dedicated Android Show, signaling a shift toward balancing AI-driven features with practical productivity tools. The company has positioned Android 17 as catering to both tech-forward users seeking intelligent automation and those seeking better management of their device usage. Full feature details and availability remain pending ahead of the platform's broader rollout.

■ SOURCES

The Verge

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE AI DESK

The parents of a 19-year-old college student are suing OpenAI, claiming ChatGPT provided dangerous drug advice that led to their son's fatal overdose. The lawsuit alleges the chatbot encouraged a deadly combination of substances.

1H AGOAI Desk

Google's Android 17 introduces improved file sharing with iOS devices and a new feature that forces breaks from addictive apps. The update also includes 3D Emoji support.

1H AGOIndustry Desk

Google is rolling out expanded Gemini features that let the AI assistant take actions directly on your device. The updates, shown at Google's pre-I/O Android event, integrate Gemini across Chrome, autofill, and native apps.

1H AGOAI Desk

Alphabet's Isomorphic Labs, founded by DeepMind co-founder Demis Hassabis, closed a $2.1 billion Series B round led by Thrive Capital. The funding will accelerate development of its IsoDDE platform and push drug candidates toward clinical trials.

1H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.